Wedgewood Partners’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13.7M | Sell |
170,969
-9,913
| -5% | -$817K | 2.83% | 19 |
|
|
2025
Q4 | $15.4M | Sell |
180,882
-3,819
| -2% | -$313K | 2.88% | 17 |
|
|
2025
Q3 | $14.4M | Buy |
184,701
+6,667
| +4% | +$521K | 2.62% | 17 |
|
|
2025
Q2 | $14.3M | Sell |
178,034
-13,784
| -7% | -$1.03M | 2.77% | 17 |
|
|
2025
Q1 | $14.7M | Sell |
191,818
-147,618
| -43% | -$10.6M | 2.97% | 16 |
|
|
2024
Q4 | $25.1M | Sell |
339,436
-19,821
| -6% | -$1.39M | 4.95% | 13 |
|
|
2024
Q3 | $23.9M | Buy |
359,257
+4,830
| +1% | +$351K | 4.34% | 13 |
|
|
2024
Q2 | $23.2M | Buy |
354,427
+108,976
| +44% | +$9.65M | 4.74% | 12 |
|
|
2024
Q1 | $22.1M | Sell |
245,451
-5,201
| -2% | -$437K | 4.43% | 13 |
|
|
2023
Q4 | $21.6M | Buy |
250,652
+56,855
| +29% | +$3.96M | 4.55% | 14 |
|
|
2023
Q3 | $13.4M | Sell |
193,797
-121,376
| -39% | -$9.75M | 3.21% | 14 |
|
|
2023
Q2 | $29.7M | Sell |
315,173
-14,897
| -5% | -$1.29M | 4.79% | 13 |
|
|
2023
Q1 | $27.3M | Sell |
330,070
-3,690
| -1% | -$290K | 4.63% | 12 |
|
|
2022
Q4 | $24.9M | Buy |
333,760
+2,133
| +0.6% | +$164K | 4.57% | 9 |
|
|
2022
Q3 | $27.4M | Sell |
331,627
-9,062
| -3% | -$872K | 5.16% | 9 |
|
|
2022
Q2 | $32.4M | Sell |
340,689
-17,531
| -5% | -$1.81M | 5.6% | 8 |
|
|
2022
Q1 | $42.2M | Buy |
358,220
+5,071
| +1% | +$569K | 5.95% | 7 |
|
|
2021
Q4 | $45.7M | Sell |
353,149
-119,478
| -25% | -$13.9M | 6.07% | 5 |
|
|
2021
Q3 | $53.5M | Sell |
472,627
-10,909
| -2% | -$1.25M | 7.55% | 1 |
|
|
2021
Q2 | $50.1M | Sell |
483,536
-30,352
| -6% | -$2.86M | 7.26% | 4 |
|
|
2021
Q1 | $43M | Sell |
513,888
-81,068
| -14% | -$6.85M | 6.62% | 4 |
|
|
2020
Q4 | $54.3M | Sell |
594,956
-36,762
| -6% | -$3.05M | 8.07% | 2 |
|
|
2020
Q3 | $50.4M | Sell |
631,718
-36,824
| -6% | -$2.87M | 7.97% | 2 |
|
|
2020
Q2 | $46.2M | Sell |
668,542
-43,058
| -6% | -$3.06M | 7.83% | 4 |
|
|
2020
Q1 | $44.7M | Sell |
711,600
-410,586
| -37% | -$29.6M | 8.48% | 2 |
|
|
2019
Q4 | $87.3M | Sell |
1,122,186
-314,181
| -22% | -$24.5M | 8.85% | 2 |
|
|
2019
Q3 | $105M | Sell |
1,436,367
-124,512
| -8% | -$8.75M | 9.33% | 2 |
|
|
2019
Q2 | $96.1M | Sell |
1,560,879
-421,578
| -21% | -$25.5M | 8.14% | 4 |
|
|
2019
Q1 | $126M | Sell |
1,982,457
-480,939
| -20% | -$27.4M | 9.23% | 1 |
|
|
2018
Q4 | $126M | Buy |
2,463,396
+6,516
| +0.3% | +$330K | 8.35% | 3 |
|
|
2018
Q3 | $143M | Sell |
2,456,880
-217,350
| -8% | -$10.6M | 7.15% | 4 |
|
|
2018
Q2 | $130M | Sell |
2,674,230
-722,793
| -21% | -$33.7M | 6.55% | 5 |
|
|
2018
Q1 | $158M | Sell |
3,397,023
-622,263
| -15% | -$27M | 7.27% | 3 |
|
|
2017
Q4 | $151M | Sell |
4,019,286
-9,855
| -0.2% | -$362K | 6.11% | 6 |
|
|
2017
Q3 | $147M | Buy |
4,029,141
+1,445,097
| +56% | +$55.1M | 5.01% | 11 |
|
|
2017
Q2 | $102M | Sell |
2,584,044
-827,172
| -24% | -$30.2M | 3.12% | 20 |
|
|
2017
Q1 | $107M | Buy |
+3,411,216
| New | +$107M | 2.75% | 19 |
|
Other funds holding EW
VCM
VPM
Wedgewood Partners's EW Position: Q1 2026 in Review
Wedgewood Partners reduced its Edwards Lifesciences (EW) stake by 5.5% in Q1 2026, selling an estimated $817K and leaving 170,969 shares worth $13.7M. The position accounts for 2.83% of the portfolio, ranked #19.
Wedgewood Partners first reported a position in EW in Q1 2017 and has held it in 37 quarters since. The position peaked at $158M in Q1 2018. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Wedgewood Partners held 170,969 shares of Edwards Lifesciences worth $13.7M as of Q1 2026.
- Wedgewood Partners sold 9,913 Edwards Lifesciences shares in Q1 2026, an estimated $817K.
- Edwards Lifesciences made up 2.83% of Wedgewood Partners's portfolio in Q1 2026, its #19 holding.
- Wedgewood Partners first reported a position in Edwards Lifesciences in Q1 2017 and has held it in 37 quarters since.
- Wedgewood Partners's Edwards Lifesciences position peaked at $158M in Q1 2018.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Wedgewood Partners's 13F filing for Q1 2026, filed 15 May 2026.